Atty. Dkt. No. 065691/0216

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Jean-Claude CHERMANN et al.

Title: VACCINE AGAINST INFECTIOUS AGENTS HAVING AN INTRACELLULAR PHASE, COMPOSITION FOR THE TREATMENT AND PREVENTION OF HIV INFECTIONS, ANTIBODIES AND METHOD OF DIAGNOSIS

Appl. No.: Unassigned

Filing Date: 04/06/2001

Examiner: Unassigned

Art Unit: Unassigned

PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with 37 CFR §1.121, please substitute for original claims 1 and 7 the following rewritten versions of the same claims, as amended. The changes are shown explicitly in the attached "Version with Markings to Show Changes Made."

IN THE SPECIFICATION:

Page 1, between lines 3 and 4, insert --This application is a divisional of Serial No. 08/973,551 filed February 19, 1998, which is a national stage of PCT/FR96/01006 filed June 28, 1996, which is a continuation of 09/599,549 filed June 23, 2000--.

Page 4, line 10, after "following" insert --(SEQ ID NOS 1-3, respectively)--;

line 23, after "B2G2.2" insert --(SEQ IS NOS 4-6, respectively)--;

line 29, after "modifications" insert --(SEQ ID NOS 7-12, respectively)--.

Page 5, line 4, after "site" insert --(SEQ ID NOS 13-16, respectively);

line 11, after "pigs)" insert --(SEQ ID NOS 17-22, respectively)--;

line 18, after "ID" insert --(NOS)--.

Page 6, line 12, after "RTPKIQV" insert --(SEQ ID NO:4)--.

Page 13, line 8, after "(RTPKIQV)" insert --(SEQ ID NO:4)--;

line 10, after "RTPKIQVGY" insert --(SEQ ID NO:23)--.

Page 15, line 17, after "(V3)" insert --(SEQ ID NO:24)--;

line 18, after "R7V" insert --(SEQ ID NO:4)--;

line 19, after "R7V" insert --(SEQ ID NO:4)--;

line 27, after "primer" insert --(SEQ ID NO:25)--;

line 28, after "primer" insert --(SEQ ID NO:26)--;

line 30, after "primer" insert --(SEQ ID NO:27)--;

line 31, after "primer" insert --(SEQ ID NO:28)--.

IN THE CLAIMS:

8. (Amended) Composition according to claim 4, characterized in that the peptide has the R7V sequence.

9. (Amended) Composition according to claim 4, characterized in that it comprises several peptides.

10. (Amended) Composition according to claim 4, characterized in that the carrier system is chosen from albumins, KLH and MAP.

11. (Amended) Composition according to claim 4, characterized in that it comprises, in addition, nonspecific immunity adjuvants.

15 (Amended) Composition according to claim 12, characterized in that the DNA sequence is carried by an expression vector.

18. (Amended) Composition according to claim 15, characterized in that the expression vector is a bacterial plasmid.

19. (Amended) Composition according to claim 15, characterized in that the expression vector consists of all or part of a defective and/or nonpathogenic virus.

20. (Amended) Composition according to claim 1, characterized inthat the peptide is expressed in a host cell.

22. (Amended) Antibodies directed against a peptide used in one of the compositions according to claim 1.

REMARKS

Applicants respectfully request that the foregoing amendments to Claims 8-11, 15, 16-20 and 22 be entered in order to avoid this application incurring a surcharge for the presence of one or more multiple dependent claims.

Respectfully submitted,

Date April 6, 2001

By Philip J. Articola Reg. No. 38819
for Stephen B. Maebius
Attorney for Applicant
Registration No. 35,264

FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5109
Telephone: (202) 672-5569
Facsimile: (202) 672-5399

VERSION WITH MARKINGS TO SHOW CHANGES MADE

8. (Amended) Composition according to [one of Claims 4 to 7] claim 4, characterized in that the peptide has the R7V sequence.

9. (Amended) Composition according to [one of Claims 4 to 8] claim 4, characterized in that it comprises several peptides.

10. (Amended) Composition according to [one of Claims 4 to 9] claim 4, characterized in that the carrier system is chosen from albumins, KLH and MAP.

11. (Amended) Composition according to [one of Claims 4 to 10] claim 4, characterized in that it comprises, in addition, nonspecific immunity adjuvants.

15 (Amended) Composition according to [one of Claims 12 to 14] claim 12, characterized in that the DNA sequence is carried by an expression vector.

18. (Amended) Composition according to [one of Claims 15 to 17] claim 15, characterized in that the expression vector is a bacterial plasmid.

19. (Amended) Composition according to [one of Claims 15 to 18] claim 15, characterized in that the expression vector consists of all or part of a defective and/or nonpathogenic virus.

20. (Amended) Composition according to [one of Claims 1 to 19] claim 1, characterized inthat the peptide is expressed in a host cell.

22. (Amended) Antibodies directed against a peptide used in one of the compositions according to [one of Claims 1 to 21] claim 1.